Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia

NCT01626456 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT01626456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01626456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
April 30, 2015
Enrollment
478 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia